We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Kimberley
Reeves
kimberley.reeves@manchester.ac.uk
Prof
Ananya
Choudhury
ananya.choudhury@nhs.net
Malignant neoplasms of urinary tract
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Studies (including Caffo et al 2016, Choudhury et al 2011) have shown that the combination of radiotherapy with the radiosensitiser, gemcitabine, improved the outcome of bladder cancer patients and this chemoradiotherapy treatment is now being offered to patients. This may have several consequences for the use of hypoxia modification in bladder cancer treatment. It will be important to know if the benefits of gemcitabine are due to increased response rates in patients with hypoxic tumours, negating the need for hypoxia modification. Conversely the benefit of gemcitabine addition may be due to a general increase in response rate irrespective of tumour oxygenation, in which case patients with hypoxic tumours would still benefit from modification strategies. Given that the interaction of gemcitabine, radiotherapy and hypoxia modification could result in increased radiotoxicity it is crucial that these therapies are targeted to the correct patient population to maximise benefit.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Not stated
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Ananya
Choudhury
ananya.choudhury@nhs.net
Dr
Kimberley
Reeves
kimberley.reeves@manchester.ac.uk
The study is sponsored by University of Manchester and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49354
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
